^
Association details:
| Biomarker: | SDC4-ROS1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P88.02 - DC4-ROS1 Fusion as a Mechanism of Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma
Published date:
01/12/2021
Excerpt:
Herein we present a 37-year-old never-smoker Chinese female with an EGFR exon 19 deletion who was diagnosed with lung adenocarcinoma (LADC)...was subjected to next generation sequencing (NGS) and a SDC4-ROS1 rearrangement was detected. The patient received crizotinib therapy and was considered to have a partial response. The progression free survival was 16.0 months.
Source:
Title:
Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling
Excerpt:
Case 2 consisted of a never smoker with a ROS1-rearranged tumor initially recognized using FISH (Table 1) and subsequently identified as harboring the SDC4-ROS1 using CGP (Table 2)...He started crizotinib 250 mg twice daily and developed minimal visual and gastrointestinal (diarrhea) effects. Within weeks of therapy, his baseline cardio-pulmonary status and performance status improved remarkably. This improvement was accompanied by radiographic improvement of lymphangitic tumor spread (non-target lesion) and a decreased of 26.8% in RECIST target lesions...
DOI:
10.1016/j.cllc.2015.03.002
